Trevi Therapeutics priced an underwritten public offering of 11,600,000 shares at $13.00 per share, raising approximately $150 million in gross proceeds.13
Underwriters, including Morgan Stanley, Leerink Partners, Cantor, and Stifel, have a 30-day option to purchase up to 1,740,000 additional shares.13
Net proceeds estimated at $141.1 million, or $162.4 million if option fully exercised, to fund Haduvio (oral nalbuphine ER) clinical trials, including Phase 3 for IPF chronic cough and Phase 2b programs.23
Combined with $171.8 million in cash and equivalents as of March 31, 2026, funds operations through 2029, excluding commercialization.2
Offering under Form S-3 filed November 13, 2025; expected to close around April 20, 2026.3
Sources:
1. https://intellectia.ai/news/stock/trevi-therapeutics-raises-150-million-in-public-offering
2. https://www.stocktitan.net/sec-filings/TRVI/8-k-trevi-therapeutics-inc-reports-material-event-d8405fad38a7.html
3. https://www.stocktitan.net/news/TRVI/trevi-therapeutics-announces-pricing-of-150-million-underwritten-02pwybf8yaby.html